H2020-JTI-IMI2-2018-16-single-stage

Suggested coordinators

Organisations that coordinated the most funded projects under this call.

• Leiden University Medical Center2 coordinated
• BVS1 coordinated
• INSERM1 coordinated
• FOUNDATION LYGATURE1 coordinated

Strong partners

Frequent participants in this call’s funded projects (research, universities, public bodies, and mixed types).

• MEDIZINISCHE UNIVERSITAET WIEN4 projects · AT
• Leiden University Medical Center2 projects · NL
• BVS2 projects · CH
• INSERM2 projects · FR
• FFUND BV2 projects · NL
• GSK2 projects · ES
• JANSSEN PHARMACEUTICA NV2 projects · BE
• UCPH2 projects · DK
• MITOLOGICS2 projects · FR
• SORBONNE UNIVERSITE2 projects · FR

Industry partners

Companies and SMEs that appear often in this call’s historical projects.

• BVS2 projects · sme
• FFUND BV2 projects · sme
• GSK2 projects · company
• JANSSEN PHARMACEUTICA NV2 projects · company
• MITOLOGICS2 projects · sme
• BioVersys SAS1 projects · sme
• EVOTEC INTERNATIONAL GMBH1 projects · sme
• GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED1 projects · company
• INSERM TRANSFERT SA1 projects · company
• NOSOPHARM1 projects · sme

Typical consortium size

Derived from historical funded projects linked to this call.

Partners per project

median 9 · avg 8.4

range 3 – 13 organisations

Country spread (sample)

9 countries

7–11 partner organisations (from median 9.0 in this call’s projects) · 9 countries appear often in the participant sample

Similar past projects

Largest EU contributions in this call — useful references for consortium patterns.

• GNA NOW€12,299,995
• TRIC-TB€6,926,375
• RespiriTB€6,840,000
• RespiriNTM€5,687,984
• AB-DiRecT€3,429,217